TW201611830A - Pharmaceutical formulation for reducing bladder spasms and method of use thereof - Google Patents
Pharmaceutical formulation for reducing bladder spasms and method of use thereofInfo
- Publication number
- TW201611830A TW201611830A TW104114896A TW104114896A TW201611830A TW 201611830 A TW201611830 A TW 201611830A TW 104114896 A TW104114896 A TW 104114896A TW 104114896 A TW104114896 A TW 104114896A TW 201611830 A TW201611830 A TW 201611830A
- Authority
- TW
- Taiwan
- Prior art keywords
- bladder spasms
- pharmaceutical formulation
- reducing bladder
- effective amount
- reducing
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Methods and compositions for reducing bladder spasms are disclosed. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of acetaminophen and an effective amount of at least one non-steroidal anti-inflammatory drug (NSAID). In another embodiment, a method for reducing bladder spasms comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of at least one prostaglandin (PG) pathway inhibitor, wherein the at least one PG pathway inhibitor is not acetaminophen or an NSAID.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/495,134 | 2014-09-24 | ||
US14/495,134 US20150010599A1 (en) | 2010-07-08 | 2014-09-24 | Pharmaceutical formulation for reducing bladder spasms and method of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201611830A true TW201611830A (en) | 2016-04-01 |
TWI618535B TWI618535B (en) | 2018-03-21 |
Family
ID=56360653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104114896A TWI618535B (en) | 2014-09-24 | 2015-05-11 | Pharmaceutical formulation for reducing bladder spasms and method of use thereof |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR100515A1 (en) |
TW (1) | TWI618535B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112704727A (en) * | 2021-01-12 | 2021-04-27 | 重庆医科大学附属第二医院 | Application of terlipressin in preparation of medicine for treating dynamic ileus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006127096A2 (en) * | 2005-05-20 | 2006-11-30 | Omeros Corporation | Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures |
-
2015
- 2015-05-11 TW TW104114896A patent/TWI618535B/en not_active IP Right Cessation
- 2015-05-18 AR ARP150101543A patent/AR100515A1/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112704727A (en) * | 2021-01-12 | 2021-04-27 | 重庆医科大学附属第二医院 | Application of terlipressin in preparation of medicine for treating dynamic ileus |
CN112704727B (en) * | 2021-01-12 | 2023-05-16 | 重庆医科大学附属第二医院 | Application of terlipressin in preparation of medicament for dynamic intestinal obstruction |
Also Published As
Publication number | Publication date |
---|---|
AR100515A1 (en) | 2016-10-12 |
TWI618535B (en) | 2018-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017000902A1 (en) | Ror-gamma inhibitor dihydropyrrolopyridines | |
MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
MY196173A (en) | Cot Modulators And Methods Of Use Thereof | |
PH12016500649A1 (en) | Combinations of histone deactylase inhibitors and immunomodulatory drugs | |
CL2015002164A1 (en) | Combined formulation of two antiviral compounds. | |
PH12016501790B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
PH12016501788B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
BR112016022062A8 (en) | combination, pharmaceutical composition, use of a combination or a pharmaceutical composition, and pharmaceutical product | |
PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
WO2014153009A3 (en) | Thiosaccharide mucolytic agents | |
MX2022001796A (en) | Methods and compositions to inhibit symptoms associated with veisalgia. | |
WO2014153495A3 (en) | Novel stat3 inhibitors | |
AU2016204294A1 (en) | Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor | |
BR112016028518A2 (en) | pharmaceutical compositions comprising dgla and use thereof | |
EA201892539A1 (en) | PYRIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION AS AOS3 Inhibitors | |
ECSP16086232A (en) | (R) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | |
MX2016016039A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof. | |
ECSP15050273A (en) | ORAL FORMULATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | |
CR20160353A (en) | CHOLESTERILE ESTER TRANSFER PROTEIN INHIBITOR (CETP) AND PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THE INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | |
MX2017003878A (en) | Pharmaceutical formulation for reducing bladder spasms and method of use thereof. | |
TW201611830A (en) | Pharmaceutical formulation for reducing bladder spasms and method of use thereof | |
MX2014005153A (en) | Production method and sublingual pharmaceutical composition of ketorolac tromethamine and tramadol hydrochloride used for pain. | |
MX2014005152A (en) | Pharmaceutical composition for the treatment of allopathic pain, using ketorolac tromethamine and tramadol hydrochloride as an active ingredient. | |
AR100729A1 (en) | PHARMACEUTICAL FORMULATION TO REDUCE THE FREQUENCY OF MICTION AND METHOD FOR USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |